{"organizations": [], "uuid": "ca0a7d522f727161b60d78c1af37abfaf36b669e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180227.html", "section_title": "Archive News &amp; Video for Tuesday, 27 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-poxel-presents-preclinical-proof-o/brief-poxel-presents-preclinical-proof-of-concept-data-for-pxl770-idUSFWN1QH02B", "country": "US", "domain_rank": 408, "title": "BRIEF-Poxel Presents Preclinical Proof-Of-Concept Data For Pxl770", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.718, "site_type": "news", "published": "2018-02-27T15:58:00.000+02:00", "replies_count": 0, "uuid": "ca0a7d522f727161b60d78c1af37abfaf36b669e"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-poxel-presents-preclinical-proof-o/brief-poxel-presents-preclinical-proof-of-concept-data-for-pxl770-idUSFWN1QH02B", "ord_in_thread": 0, "title": "BRIEF-Poxel Presents Preclinical Proof-Of-Concept Data For Pxl770", "locations": [], "entities": {"persons": [{"name": "poxel", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "nas", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "nash", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 27 (Reuters) - POXEL SA:\n* POXEL PRESENTS PRECLINICAL PROOF-OF-CONCEPT DATA FOR PXL770 IN NON-ALCOHOLIC STEATOHEPATITIS (NASH) AT GLOBAL NASH CONGRESS 2018\n* PXL770 IS OBSERVED TO SIGNIFICANTLY REDUCE LIVER STEATOSIS AND NAS SCORE FOLLOWING 8 WEEKS OF TREATMENT VERSUS CONTROL\n* PXL770 IS OBSERVED TO SIGNIFICANTLY REDUCE EXPRESSION OF A PANEL OF KEY GENES ASSOCIATED WITH FIBROSIS\n* WE ARE PLANNING TO INITIATE A PHASE 2A PROOF-OF-CONCEPT STUDY IN PATIENTS WITH NAFLD -CEO\n* STUDY IS EXPECTED TO BEGIN DURING SECOND HALF OF 2018 * WE ARE ALSO EXPLORING OTHER METABOLIC DISEASES FOR PROOF-OF-CONCEPT STUDIES FOR PXL770 -CEO Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-27T15:58:00.000+02:00", "crawled": "2018-02-28T12:50:28.033+02:00", "highlightTitle": ""}